OBR Daily Commentary

forumImage

A Cancer-Drug Pricing Experiment Just Got More Interesting

(BloombergGadfly) Dec 8, 2017 - The results from late-stage trial data released on Friday for Pfizer’s breast cancer drug talazoparib could push an experiment in cancer-drug price competition into overdrive.

Thomas Marsland, MD (Posted: December 12, 2017)

quotesSo how many part inhibitors do we need, how many check point inhibitors are necessary? Does every company need a "me too" drug. Clearly the cost of pharmaceuticals is a major problem for all of us. One "experiment" that should be considered is including the price of a new drug as part of the approval process. If a new drug in a given class is truly interchangeable, then as part of the value proposition there should be some cost benefits to the payers and patients. quotes

Read Article arrow
Add Comment 1 Comment
forumImage

In Cancer, Talking About Bad News Can Be Good

(UC Davis Health) Nov 17, 2017 - A Journal of Clinical Oncology study may provide reassurance to oncologists worried that talking about a patient’s chances of survival may do more harm than good.

Thomas Marsland, MD (Posted: December 06, 2017)

quotesSo the glass is half full or half empty. Clearly conveying bad news is never easy but honestly is the best policy. Most patient do appreciate the truth but sometime the messenger is killed. It is difficult to offer hope and realistic expectations. In all of the changes to the idea of patient centered care seems that what patients value most is an open and honest discussion of realistic expectations. These types of discussions often require more time and indeed need to be repeated over a number of visits. Going forward the hope is the system will allow for these types of interactions.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

PET Scan Identifies Which Prostate Cancer Patients Can Benefit from Salvage Radiation Treatment

(SNMMI) Dec 4, 2017 - For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference.

Howard Sandler, MD, MS, FASTRO (Posted: December 05, 2017)

quotesPSMA PET and fluciclovine PET are rapidly changing the management of recurrent prostate cancer. Conventional imaging modalities, say bone scan or CT, would only detect recurrences at relatively high PSA levels when local management might be less optimal. However, PET imaging can now detect low volume, low PSA recurrences after surgery that are potentially amenable to local ablation with additional surgery or radiotherapy.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...